Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Card Fail. 2020 May 25;26(9):769–775. doi: 10.1016/j.cardfail.2020.04.011

Figure 4. Sacubitril/valsartan (Sac/Val) prevents cardiac hypertrophy and improves left ventricular systolic function after pressure overload to the same degree in the presence of wild type or mutant PKGIα.

Figure 4.

A. Summary data of heart mass normalized to tibia length in wild type and PKG Leucine Zipper (LZ) mutant mice on day 56 after transaortic constriction. B. LV Contractility Index (dP/dt normalized to instantaneous pressure) obtained by invasive hemodynamics at Day 56. C. LV Fractional shortening percentage (FS%) on Day 14 and Day 56 in WT and PKG LZ mutant mice treated with vehicle (Veh), or sacubitril/valsartan (Sac/Val). *, p<0.05; †, p=0.05; ‡, p<0.01 WT Day 14 vs WT Day 56; §, p<0.01 LZM Day 14 vs LZM Day 56. n=5 per sham group, 8 WT TAC Veh, 8 WT TAC Sac/Val; 11 LZM TAC Veh, 10 LZM TAC Sac/Val. A-B, data analyzed by One Way ANOVA with Tukey’s multiple comparisons test. C, data analyzed by Two Way Repeated Measures ANOVA with Sidak’s multiple comparisons test.